Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Chief Financial Officer | September 30, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date September 30, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 15,000 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Purchase · Acquired 15,000 · Balance 15,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Deciphera Pharmaceuticals, Inc.
Report date June 11, 2024 · Filed June 11, 2024
Section 16 reporting ended · disclosed 2024-06-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-06-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-06-11 · Grant · Acquired 34,157 · Balance 114,507 F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred. Row 2 · 2024-06-11 · Disposition to issuer · Disposed 72,029 · Balance 42,478 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Row 3 · 2024-06-11 · Other · Disposed 42,478 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.89 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-11 · Disposition to issuer · Disposed 85,456 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-11 · Disposition to issuer · Disposed 5,650 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-06-11 · Disposition to issuer · Disposed 103,219 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.23 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-06-11 · Disposition to issuer · Disposed 82,265 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-06-11 · Disposition to issuer · Disposed 82,000 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.48 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-06-11 · Disposition to issuer · Disposed 65,900 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.92 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-06-11 · Disposition to issuer · Disposed 69,100 · Balance 0 F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred.
F2: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the "Common Stock") for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding.
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2020 Filed Feb 20, 2020 16:10 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 42,190 | $0.00 Strike: $54.87 | $0.00 |
DisclosureSEC source: 0001209191-20-011042 · doc4.xml · derivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,190 Underlying: Common Stock · 42,190 shares Expires 2030-02-17 F2 · derivative.exercise_date: This stock option award was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments over a 4-year period following the vesting commencement date of 2/18/2020, subject to continued service through such dates. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 16:10 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantCommon Stock | 7,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-011042 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,040 F1 · shares: The reporting person was awarded 7,040 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2021, February 15, 2022, February 15, 2023 and February 15, 2024, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,359 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · derivative · entry 12 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,008 Underlying: Common Stock · 4,359 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of February 23, 2015, subject to continued service through such dates. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 100 | $58.74 | $5,874.00 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 10 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 966 | $58.14 | $56,166.14 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 9 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.73 to $58.51, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,793 | $57.22 | $159,825.24 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 8 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,066 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.70 to $57.56, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 500 | $56.26 | $28,128.00 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 7 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,859 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.67 to $56.63, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 4,359 | $1.89 | $8,238.51 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 6 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,641 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · derivative · entry 11 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,367 Underlying: Common Stock · 7,641 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of February 23, 2015, subject to continued service through such dates. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 100 | $62.25 | $6,225.00 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 5 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 200 | $59.48 | $11,896.00 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 4 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.44 to $59.52, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 1,981 | $58.16 | $115,218.92 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.96 to $58.60, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 5,360 | $57.54 | $308,407.97 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,281 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.96 to $57.95, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 16:15 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 7,641 | $1.89 | $14,441.49 |
DisclosureSEC source: 0001209191-20-001756 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-061918 · doc4.xml · derivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,008 Underlying: Common Stock · 40,000 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of February 23, 2015, subject to continued service through such dates. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 40,000 | $68.21 | $2,728,368.00 |
DisclosureSEC source: 0001209191-19-061918 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.01 to $68.64, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 16:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 40,000 | $1.89 | $75,600.00 |
DisclosureSEC source: 0001209191-19-061918 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 16:01 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-054496 · doc4.xml · derivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,008 Underlying: Common Stock · 3,750 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of February 23, 2015, subject to continued service through such dates. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 16:01 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 3,750 | $40.00 | $150,009.75 |
DisclosureSEC source: 0001209191-19-054496 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.02, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 28, 2019 Filed Oct 30, 2019 16:01 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 3,750 | $1.89 | $7,087.50 |
DisclosureSEC source: 0001209191-19-054496 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-049467 · doc4.xml · derivative · entry 4 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,758 Underlying: Common Stock · 11,250 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of February 23, 2015, subject to continued service through such dates. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 3,090 | $35.43 | $109,467.89 |
DisclosureSEC source: 0001209191-19-049467 · doc4.xml · nonDerivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.06 to $35.70, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 8,160 | $34.80 | $283,972.08 |
DisclosureSEC source: 0001209191-19-049467 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,160 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $35.03, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 11, 2019 Filed Sep 13, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 11,250 | $1.89 | $21,262.50 |
DisclosureSEC source: 0001209191-19-049467 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 19:55 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-045820 · doc4.xml · derivative · entry 5 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,008 Underlying: Common Stock · 11,250 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 19:55 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 400 | $42.92 | $17,167.00 |
DisclosureSEC source: 0001209191-19-045820 · doc4.xml · nonDerivative · entry 4 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.90 to $42.97, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 19:55 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 3,586 | $42.25 | $151,520.69 |
DisclosureSEC source: 0001209191-19-045820 · doc4.xml · nonDerivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.71 to $42.61, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 19:55 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 7,264 | $40.69 | $295,567.80 |
DisclosureSEC source: 0001209191-19-045820 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,986 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.11 to $41.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 13, 2019 19:55 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 11,250 | $1.89 | $21,262.50 |
DisclosureSEC source: 0001209191-19-045820 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:03 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 177 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-038450 · doc4.xml · derivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,258 Underlying: Common Stock · 177 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:03 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 177 | $25.00 | $4,425.00 |
DisclosureSEC source: 0001209191-19-038450 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:03 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 177 | $1.89 | $334.53 |
DisclosureSEC source: 0001209191-19-038450 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:08 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,100 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-034713 · doc4.xml · derivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,435 Underlying: Common Stock · 2,100 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:08 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 2,100 | $25.20 | $52,926.93 |
DisclosureSEC source: 0001209191-19-034713 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:08 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 2,100 | $1.89 | $3,969.00 |
DisclosureSEC source: 0001209191-19-034713 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2019 Filed May 23, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-032277 · doc4.xml · derivative · entry 6 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,535 Underlying: Common Stock · 100 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates. Read SEC document |
| May 22, 2019 Filed May 23, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 100 | $25.00 | $2,500.00 |
DisclosureSEC source: 0001209191-19-032277 · doc4.xml · nonDerivative · entry 4 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 22, 2019 Filed May 23, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 100 | $1.89 | $189.00 |
DisclosureSEC source: 0001209191-19-032277 · doc4.xml · nonDerivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2019 Filed May 23, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,373 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-032277 · doc4.xml · derivative · entry 5 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,635 Underlying: Common Stock · 1,373 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates. Read SEC document |
| May 21, 2019 Filed May 23, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 1,373 | $25.07 | $34,418.78 |
DisclosureSEC source: 0001209191-19-032277 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2019 Filed May 23, 2019 16:04 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 1,373 | $1.89 | $2,594.97 |
DisclosureSEC source: 0001209191-19-032277 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 3, 2019 16:07 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,500 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-027308 · doc4.xml · derivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,008 Underlying: Common Stock · 13,500 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates. Read SEC document |
| May 01, 2019 Filed May 3, 2019 16:07 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 13,500 | $22.93 | $309,523.95 |
DisclosureSEC source: 0001209191-19-027308 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.34 to $23.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2019 Filed May 3, 2019 16:07 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 13,500 | $1.89 | $25,515.00 |
DisclosureSEC source: 0001209191-19-027308 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 20:37 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-011841 · doc4.xml · derivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,508 Underlying: Common Stock · 1,500 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 20:37 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 1,500 | $30.00 | $45,000.00 |
DisclosureSEC source: 0001209191-19-011841 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 20:37 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionCommon Stock | 1,500 | $1.89 | $2,835.00 |
DisclosureSEC source: 0001209191-19-011841 · doc4.xml · nonDerivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 16:14 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $26.35 | $0.00 |
DisclosureSEC source: 0001209191-19-006407 · doc4.xml · derivative · entry 1 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-29 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments following the vesting commencement date of January 1, 2019 , subject to continued service through such dates. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 16:54 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001209191-19-003079 · doc4.xml · derivative · entry 3 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,008 Underlying: Common Stock · 5,000 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 16 equal installments over a 4-year period following the vesting commencement date of 2/23/2015, subject to continued service through such dates. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 16:54 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | SaleCommon Stock | 5,000 | $25.18 | $125,900.00 |
DisclosureSEC source: 0001209191-19-003079 · doc4.xml · nonDerivative · entry 2 Kelly Thomas Patrick · CIK 0001410514 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.39. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.